Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  29 (2025)
Volume  28 (2024)
Volume  27 (2023)
Volume  26 (2022)
Volume  25 (2021)
Volume  24 (2020)
Volume  23 (2019)
Volume  22 (2018)
Volume  21 (2017)
Volume  20 (2016)
Volume  19 (2015)
Volume  18 (2014)
Volume  17 (2013)
Volume  16 (2012)
Volume  15 (2011)
Volume  14 (2010)
Volume  13 (2009)
Volume  12 (2008)
Volume  11 (2007)
Volume  10 (2006)
Volume  9 (2005)
Volume  8 (2004)
Related articles

VOLUME 29 , ISSUE 2 ( February, 2025 ) > List of Articles

Original Article

ADAMTS-13 Behavior in Thrombocytopenia of Infectious Origin in ICU Patients

V Dinesh K Gontla, Srinivas Samavedam, Narmada Aluru, Radhika Rudravarapu, Shravani Pabba, Mohammad N Shaik

Keywords : A disintegrin-like metalloproteinase and thrombospondin-like activity motif 13, ICU severity, Non-viral infections, Thrombocytopenia, Prognosis, Viral infections

Citation Information : Gontla VD, Samavedam S, Aluru N, Rudravarapu R, Pabba S, Shaik MN. ADAMTS-13 Behavior in Thrombocytopenia of Infectious Origin in ICU Patients. Indian J Crit Care Med 2025; 29 (2):143-147.

DOI: 10.5005/jp-journals-10071-24890

License: CC BY-NC 4.0

Published Online: 31-01-2025

Copyright Statement:  Copyright © 2025; The Author(s).


Abstract

Introduction: Thrombocytopenia is a common hematological abnormality in intensive care unit (ICU) patients, with varying incidence across populations. A disintegrin-like metalloproteinase and thrombospondin-like activity motif 13 (ADAMTS-13), a plasma serine protease, plays a crucial role in modulating von Willebrand factor (vWF) activity by cleaving its ultra-large (UL) multimers and preventing excess platelet aggregation. This study aimed to evaluate the association between ADAMTS-13 levels, viral and non-viral (NV) infections, and thrombocytopenia severity. Materials and methods: This Prospective observational study included adult ICU patients with thrombocytopenia, categorized into viral and non-viral groups. Thrombocytopenia severity was assessed by absolute platelet count on diagnosis day. Statistical analyses evaluated correlations between ADAMTS-13 levels, thrombocytopenia severity, and clinical outcomes, including bleeding episodes, transfusion needs, and overall patient outcomes. Results: Among 72 patients (30 viral, 42 non-viral), lower ADAMTS-13 activity correlated significantly with thrombocytopenia severity in both groups (p < 0.05), with a greater deficiency observed in NV cases. A disintegrin-like metalloproteinase and thrombospondin-like activity motif 13 levels were associated with bleeding episodes, transfusion requirements, and thrombocytopenia progression in both groups but did not predict increased transfusion needs despite lower platelet counts. Conclusion: This study highlights an association between reduced ADAMTS-13 activity, infection type, and thrombocytopenia severity, especially in NV infections. A disintegrin-like metalloproteinase and thrombospondin-like activity motif 13 (ADAMTS-13) depletion and increased vWF activity may contribute to infection-related thrombocytopenia pathogenesis. These findings suggest that ADAMTS-13 levels could aid in assessing thrombocytopenia severity and prognosis, informing early management strategies and transfusion guidelines. Clinical significance: This study found that low ADAMTS-13 activity is associated with higher disease severity in both viral and non-viral infections, particularly in NV cases. While thrombocytopenia correlated with reduced ADAMTS-13 activity, it did not lead to increased platelet transfusions.

PDF Share
  1. Crowther MA, Cook DJ, Meade MO, Griffith LE, Guyatt GH, Arnold DM, et al. Thrombocytopenia in medical-surgical critically ill patients: Prevalence, incidence, and risk factors. J Crit Care 2005;20(4):348–353. DOI: 10.1016/j.jcrc.2005.09.008.
  2. Williamson DR, Lesur O, Tétrault JP, Nault V, Pilon D. Thrombocytopenia in the critically ill: Prevalence, incidence, risk factors, and clinical outcomes. Can J Anaesth 2013;60(7):641–651. DOI: 10.1007/s12630-013-9933-7.
  3. Upadhya SRS, Mahabala C, Kamat JG, Jeganathan J, Kumar S, Prabhu MV. Plasmapheresis in sepsis-induced thrombotic microangiopathy: A case series. Indian J Crit Care Med 2020;24(3):195–199. DOI: 10.5005/jp-journals-10071-23374.
  4. Zander CB, Cao W, Zheng XL. ADAMTS13 and von Willebrand factor interactions. Curr Opin Hematol 2015;22(5):452–459. DOI: 10.1097/MOH.0000000000000169.
  5. Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, Ishikawa M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005;106(3):922–924. DOI: 10.1182/blood-2005-01-0152.
  6. Gavali AS, Shelgaonkar J, Bartakke S. Thrombotic thrombocytopenic purpura in a case of dengue fever: A rare presentation. Indian J Crit Care Med 2017;21(4):226–228. DOI: 10.4103/ijccm.IJCCM_27_16.
  7. Aibar J, Castro P, Espinosa G, Fernández S, Hernández C, Rinaudo M, et al. ADAMTS-13 in critically ill patients with septic syndromes and noninfectious systemic inflammatory response syndrome. Shock 2015;43(6):556–562. DOI: 10.1097/SHK.0000000000000341.
  8. Lin JJ, Chan OW, Hsiao HJ, Wang Y, Hsia SH, Chiu CH. Decreased ADAMTS13 activity is associated with disease severity and outcome in pediatric severe sepsis. Medicine (Baltimore) 2016;95(16):e3374. DOI: 10.1097/MD.0000000000003374.
  9. Schwameis M, Schörgenhofer C, Assinger A, Steiner MM, Jilma B. VWF excess and ADAMTS13 deficiency: A unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thromb Haemost 2015;113(4):708–718. DOI: 10.1160/TH14-09-0731.
  10. Hovinga JAK, Zeerleder S, Kessler P, Romani de Wit T, van Mourik JA, Hack CE, et al. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost 2007;5(11):2284–2290. DOI: 10.1111/j.1538-7836.2007.02743.x.
  11. Claus RA, Bockmeyer CL, Budde U, Kentouche K, Sossdorf M, Hilberg T, et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost 2009;101(2):239–247. DOI: 10.1160/TH08-03-0161.
  12. Djamiatun K, van der Ven AJ, de Groot PG, Faradz SM, Hapsari D, Dolorosa MA, et al. Severe dengue is associated with consumption of von Willebrand factor and its cleaving enzyme ADAMTS-13. PLoS Negl Trop Dis 2012;6(5):e1628. DOI: 10.1371/journal.pntd.0001628.
  13. Favaloro EJ, Henry BM, Lippi G. Increased VWF and decreased ADAMTS-13 in COVID-19: Creating a milieu for (micro)thrombosis. Semin Thromb Hemost 2021;47(4):400–418. DOI: 10.1055/s-0041-1727282.
  14. Peigne V, Azoulay E, Coquet I, Mariotte E, Darmon M, Legendre P, et al. The prognostic value of ADAMTS13 deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation. Crit Care 2013;17(6):R273. DOI: 10.1186/cc13115.
  15. Bockmeyer CL, Claus RA, Budde U, Kentouche K, Schneppenheim R, Lösche W, et al. Inflammation-associated ADAMTS-13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica 2008;93(1):137–140. DOI: 10.3324/haematol.11677.
  16. Azfar MF, Khan MF, Habib SS, Aseri ZA, Zubaidi AM, Aguila DO, et al. Prognostic value of ADAMTS-13 deficiency in patients with severe sepsis and septic shock. Clin Invest Med 2017;40(2):E49–E58. DOI: 10.25011/cim.v40i2.28195.
  17. Rautiainen L, Cirko A, Pavare J, Balmaks R, Grope I, Katirlo I, et al. Assessment of ADAMTS-13 level in hospitalized children with serious bacterial infections as a possible prognostic marker. Medicina (Kaunas) 2019;55(8):503. DOI: 10.3390/medicina55080503.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.